Catechol-o-methyltransferase and Alzheimer's disease: A review of biological and genetic findings

CNS and Neurological Disorders - Drug Targets

Volumn 11, Issue 3, 2012, Pages 299-305

  Serretti, Alessandro ^a   Olgiati, Paolo ^a  

^a UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

Alzheimer; Catechol O mehyltransferase; Catechol O mehyltransferase gene; Catechol O mehyltransferase inhibitor; Dementia

Indexed keywords

APOLIPOPROTEIN E; CATECHOL METHYLTRANSFERASE; CYANOCOBALAMIN; DOPAMINE; ENTACAPONE; ESTROGEN; HOMOCYSTEINE; TOLCAPONE;

ALLELE; ALZHEIMER DISEASE; ARTICLE; CELL MIGRATION; DOPAMINE URINE LEVEL; DRUG BIOAVAILABILITY; DRUG EFFICACY; EPISODIC MEMORY; FUNCTIONAL MAGNETIC RESONANCE IMAGING; GENETIC ASSOCIATION; GENETIC VARIABILITY; HUMAN; NONHUMAN; PATHOPHYSIOLOGY; PHENOTYPE; PROTEIN FUNCTION; SIGNAL TRANSDUCTION; SINGLE NUCLEOTIDE POLYMORPHISM; WORKING MEMORY;

EID: 84861739730     PISSN: 18715273     EISSN: 19963181     Source Type: Journal    
DOI: 10.2174/187152712800672472     Document Type: Article

References (99)

1. Birks, J. Cholinesterase inhibitors for Alzheimer's disease. Cochrane Database Syst. Rev., 2006, CD005593.
2. Raina, P.; Santaguida, P.; Ismaila, A.; Patterson, C.; Cowan, D.; Levine, M.; Booker, L.; Oremus, M. Effectiveness of cholinesterase inhibitors and memantine for treating dementia: evidence review for a clinical practice guideline Ann. Intern. Med., 2008, 148, 379-397.
3. Parnowski, T. Depression and Alzhemer's disease. Neurol. Neurochir. Pol., 1999, 33(Suppl 1), 39-50.
4. Arbus, C.; Andrieu, S.; Amouyal-Barkate, K.; Nourhashemi, F.; Schmitt, L.; Vellas, B. Depressive symptoms in Alzheimer's disease: preliminary results of the REAL. FR study. Rev. Med. Intern., 2003, 24(Suppl 3), 325s-332s.
5. Weiner, M.F.; Doody, R.S.; Sairam, R.; Foster, B.; Liao, T.Y. Prevalence and incidence of major depressive disorder in Alzheimer's disease: findings from two databases. Dement. Geriatr. Cogn. Disord., 2002, 13, 8-12.
6. Perez-Madrinan, G.; Cook, S.E.; Saxton, J.A.; Miyahara, S.; Lopez, O.L.; Kaufer, D.I.; Aizenstein, H.J.; DeKosky, S.T.; Sweet, R.A. Alzheimer disease with psychosis: excess cognitive impairment is restricted to the misidentification subtype. Am. J. Geriatr. Psychiatry, 2004, 12, 449-456.
7. Ballard, C.; Creese, B.; Corbett, A.; Aarsland, D. Atypical antipsychotics for the treatment of behavioral and psychological symptoms in dementia, with a particular focus on longer term outcomes and mortality. Expert Opin. Drug Saf., 2010, 10, 35-43.
8. Kaenmaki, M.; Tammimaki, A.; Myohanen, T.; Pakarinen, K.; Amberg, C.; Karayiorgou, M.; Gogos, J.A.; Mannisto, P.T. Quantitative role of COMT in dopamine clearance in the prefrontal cortex of freely moving mice. J. Neurochem., 2010, 114, 1745-1755.
9. Grossman, M.H.; Emanuel, B.S.; Budart, M.L. Chromosomal mapping of the human catechol-O-methyltransferase gene to 22q11.1----q11.2 Genomics, 1992, 12, 822-825.
10. Lotta, T.; Vidgren, J.; Tilgmann, C.; Ulmanen, I.; Melen, K.; Julkunen, I.; Taskinen, J. Kinetics of human soluble and membrane-bound catechol O-methyltransferase: a revised mechanism and description of the thermolabile variant of the enzyme. Biochemistry, 1995, 34, 4202-4210.
11. Egan, M.F.; Goldberg, T.E.; Kolachana, B.S.; Callicott, J.H.; Mazzanti, C.M.; Straub, R.E.; Goldman, D.; Weinberger, D.R. Effect of COMT Val108/158 Met genotype on frontal lobe function and risk for schizophrenia. PNAS, 2001, 98, 6917-6922.
12. Liu, L.; Li, Q.; Li, N.; Ling, J.; Liu, R.; Wang, Y.; Sun, L.; Chen, XH; Bi, K. Simultaneous determination of catecholamines and their metabolites related to Alzheimer's disease in human urine. J. Sep. Sci., 2011, 34, 1198-1204.
13. Koch, G.;Esposito, Z.; Codecà, C.; Mori, F.; Kusayanagi, H.; Monteleone, F.; Di Lorenzo, F.; Bernardi, G.; Martorana, A. Altered dopamine modulation of LTD-like plasticity in Alzheimer's disease patients. Clin. Neurophysiol., 2011, 122, 703-707.
14. Martorana, A.; Mori, F.; Esposito, Z.; Kusayanagi, H.; Codecà, C.; Sancesano, G.; Bernardi, G.; Koch, G. Dopamine modulates cholinergic cortical excitability in Alzheimer's disease patients. Neuropsychopharmacology, 2011, 34, 2323-2328.
15. Sato, N.; Ueki, A.; Ueno, H.; Shinjo, H.; Morita, Y. Dopamine D3 receptor gene polymorphism influences on behavioral and psychological symptoms of dementia (BPSD) in mild dementia of Alzheimer's type. J. Alzheimer Dis., 2009, 17, 441-448.
16. Pritchard, A.L.; Pritchard, C.W.; Bentham, P.; Lendon, CL. Investigation of the role of the dopamine transporter in susceptibility to behavioural and psychological symptoms of patients with probable Alzheimer's disease. Dement. Geriatr. Cogn. Disord., 2008, 26, 257-260.
17. Seeman, P.; Caruso, C.; Lasaga, M. Memantine agonist action at dopamine D2High receptors. Synapse, 2008, 62, 149-153.
18. Spanagel, R.; Eilbacher, B.; Wilke, R. Memantine-induced dopamine release in the prefrontal cortex and striatum of the rat - a pharmachokinetic microdialysis study. Eur. J. Pharmacol., 1994, 262, 21-26.
19. Giustizieri, M.; Cucchiaroni, M.L.; Guatteo, E.; Bernardi, G.; Mercuri, N.B.; Berretta, N. Memantine inhibits ATP-dependent K+ conductances in dopamine neurons of the rat substantia nigra pars compacta. J. Pharmacol. Exp. Ther., 2007, 322, 721-729.
20. Butterworth, M.; Lau, S.S.; Monks, T.J. 17 beta-estradiol metabolism by hamster hepatic microsomes: comparison of catechol estrogen O-methylation with catechol estrogen oxidation and glutathione conjugation. Chem. Res. Toxicol., 1996, 9, 793-799.
21. Worda, C.; Sator, M.O.; Schneeberger, C.; Jantschev, T.; Ferlitsch, K.; Huber, J.C. Influence of the catechol-O-methyltransferase (COMT) codon 158 polymorphism on estrogen levels in women. Hum. Reprod., 2003, 18, 262-266.
22. Hong, C.C.; Thompson, H.J.; Jiang, C.; Hammond, G.L.; Tritchler, D.; Yaffe, M.; Boyd, N.F. Val158Met Polymorphism in catechol- O-methyltransferase gene associated with risk factors for breast cancer. Cancer Epidemiol. Biomarkers Prev., 2003, 12, 838-847.
23. Long, J.R.; Cai, Q.; Shu, X.O.; Cai, H.; Gao, Y.T.; Zheng, W. Genetic polymorphisms in estrogen-metabolizing genes and breast cancer survival. Pharmacogenet. Genom., 2007, 17, 331-338.
24. Parl, F.F.; Dawling, S.; Roodi, N.; Crooke, P.S. Estrogen metabolism and breast cancer: a risk model. Ann. NY Acad. Sci., 2009, 1155, 68-75.
25. Suzuki, K.; Nakazato, H.; Matsui, H.; Koike, H.; Okugi, H.; Kashiwagi, B.; Nishii, M.; Ohtake, N.; Nakata, S.; Ito, K.; Yamanaka, H. Genetic polymorphisms of estrogen receptor alpha, CYP19, catechol-O-methyltransferase are associated with familial prostate carcinoma risk in a Japanese population. Cancer, 2003, 98, 1411-1416.
26. Tanaka, Y.; Sasaki, M.; Shiina, H.; Tokizane, T.; Deguchi, M.; Hirata, H.; Hinoda, Y.; Okayama, N.; Suehiro, Y.; Urakami, S.; Kawakami, T.; Kaneuchi, M.; Pookot, D.; Igawa, M.; Okuyama, A.; Ishii, N.; Dahiya, R. Catechol-O-methyltransferase gene olymorphisms in benign prostatic hyperplasia and sporadic prostate cancer. Cancer Epidemiol. Biomark. Prev., 2006, 15, 238-244.
27. Tofteng, C.L.; Abrahamsen, B.; Jensen, J.E.; Petersen, S.; Teilmann, J.; Kindmark, A.; Vestergaard, P.; Gram, J.; Langdahl, B.L.; Mosekilde, L. Two single nucleotide polymorphisms in the CYP17 and COMT Genes--relation to bone mass and longitudinal bone changes in postmenopausal women with or without hormone replacement therapy. The Danish Osteoporosis Prevention Study. Calcif. Tissue Int., 2004, 75, 123-132.
28. Lorentzon, M.; Eriksson, A.L.; Nilsson, S.; Mellstrom, D.; Ohlsson, C. Association between physical activity and BMD in young men is modulated by catechol-O-methyltransferase (COMT) genotype: the GOOD study. J. Bone Miner. Res., 2007, 22, 1165-1172.
29. Liu, X.A.; Zhu, L.Q.; Zhang, Q.; Shi, H.R.; Wang, S.H.; Wang, Q.; Wang, J.Z. Estradiol attenuates tau hyperphosphorylation induced by upregulation of protein kinase-A Neurochem. Res., 2008, 33, 1811-1820.
30. Shi, H.R.; Zhu, L.Q.; Wang, S.H.; Liu, X.A.; Tian, Q.; Zhang, Q.; Wang, Q.; Wang, J.Z. 17beta-estradiol attenuates glycogen synthase kinase-3beta activation and tau hyperphosphorylation in Akt-independent manner. J. Neural Transm., 2008, 115, 879-888.
31. Yun, S.H.; Park, K.A.; Kwon, S.; Woolley, C.S.; Sullivan, P.M.; Pasternak, J.F.; Trommer, B.L. Estradiol enhances long term potentiation in hippocampal slices from aged apoE4-TR mice. Hippocampus, 2007, 17, 1153-1157.
32. Xu, H.; Wang, R.; Zhang, Y.W.; Zhang, X. Estrogen, beta-amyloid metabolism/trafficking, and Alzheimer's disease. Ann. NY Acad. Sci., 2006, 1089, 324-342.
33. Morinaga, A.; Hirohata, M.; Ono, K.; Yamada, M. Estrogen has anti-amyloidogenic effects on Alzheimer's beta-amyloid fibrils in vitro. Biochem. Biophys. Res. Commun., 2007, 359, 697-702.
34. Simpkins, J.W.; Yi, K.D.; Yang, S.H.; Dykens, J.A. Mitochondrial mechanisms of estrogen neuroprotection. Biochim. Biophys. Acta, 2010, 1800, 1113-1120.
35. Lloret, A.; Badia, M.C.; Mora, N.J.; Ortega, A.; Pallardò, F.V.; Alonso, M.D.; Alamna, H.; Viña, J. Gender and age-dependent differences in the mitochondrial apoptogenic pathway in Alzheimer's disease. Free Radic. Biol. Med., 2008, 44, 2019-2025.
36. Liang, K.; Yang, L.; Yin, C.; Xiao, Z.; Zhang, J.; Liu, Y.; Huang, J. Estrogen stimulates degradation of beta-amyloid peptide by up-regulating neprilysin. J. Biol. Chem., 2010, 285, 935-942.
37. Porrello, E.; Monti, M.C.; Sinforiani, E.; Cairati, M.; Guaita, A.; Montomoli, C.; Govoni, S.; Racchi, M. Estrogen receptor alpha and APOEepsilon4 polymorphisms interact to increase risk for sporadic AD in Italian females. Eur. J. Neurol., 2006, 13, 639-644.
38. Craig, M.C.; Murphy, D.G. Estrogen therapy and Alzheimer's dementia. Ann. NY Acad. Sci., 2010, 1205, 245-253.
39. Clarke, R.; Smith, A.D.; Jobst, K.A.; Refsum, H.; Sutton, L.; Ueland, P.M. Folate, vitamin B12, and serum total homocysteine levels in confirmed Alzheimer disease Arch. Neurol., 1998, 55, 1449-1455.
40. McCaddon, A.; Davies, G.; Hudson, P.; Tandy, S.; Cattell, H. Total serum homocysteine in senile dementia of Alzheimer type. Int. J. Geriatr. Psychiatry, 1998, 13, 235-239.
41. Hooshmand, B.; Solomon, A.; Kareholt, I.; Leiviska, J.; Rusanen, M.; Ahtiluoto, S.; Winblad, B.; Laatikainen, T.; Soininen, H.; Kivipelto, M. Homocysteine and holotranscobalamin and the risk of Alzheimer disease: a longitudinal study. Neurology, 2010, 75, 1408-1414.
42. Annerbo, S.; Kivipelto, M.; Lokk, J. A prospective study on the development of Alzheimer's disease with regard to thyroid-stimulating hormone and homocysteine. Dement. Geriatr. Cogn. Disord., 2009, 28, 275-280.
43. Kivipelto, M.; Annerbo, S.; Hultdin, J.; Backman, L.; Viitanen, M.; Fratiglioni, L.; Lokk, J. Homocysteine and holo-transcobalamin and the risk of dementia and Alzheimers disease: a prospective study. Eur. J. Neurol., 2009, 16, 808-813.
44. Tu, M.C.; Huang, C.W.; Chen, N.C.; Chang, W.N.; Lui, C.C.; Chen, C.F.; Chen, C.; Wang, Y.L.; Lin, Y.T.; Chang, C.C. Hyperhomocysteinemia in Alzheimer dementia patients and cognitive decline after 6 months follow-up period. Acta Neurol. Taiwan, 2010, 19, 168-177.
45. Oulhaj, A.; Refsum, H.; Beaumont, H.; Williams, J.; King, E.; Jacoby, R.; Smith, A.D. Homocysteine as a predictor of cognitive decline in Alzheimer's disease. Int. J. Geriatr. Psychiatry, 2010, 25, 82-90.
46. Chen, C.S.; Chou, M.C.; Yeh, Y.C.; Yang, Y.H.; Lai, C.L.; Yen, C.F.; Liu, C.K.; Liao, Y.C. Plasma homocysteine levels and major depressive disorders in Alzheimer disease. Am. J. Geriatr. Psychiatry, 2010, 18, 1045-1048.
47. Tunbridge, E.M.; Harrison, P.J.; Warden, D.R.; Johnston, C.; Refsum, H.; Smith, A.D. Polymorphisms in the catechol-O- methyltransferase (COMT) gene influence plasma total homocysteine levels. Am. J. Med. Genet. B. Neuropsychiatr. Genet., 2008, 147B, 996-999.
48. Wang, P.N.; Liu, H.C.; Liu, T.Y.; Chu, A.; Hong, C.J.; Lin, K.N.; Chi, C.W. Estrogen-metabolizing gene COMT polymorphism synergistic APOE epsilon4 allele increases the risk of Alzheimer disease. Dement. Geriatr. Cogn. Disord., 2005, 19, 120-125.
49. Martinez, M.F.; Martin, X.E.; Alcelay, L.G.; Flores, J.C.; Valiente, J.M.; Juanbeltz, B.I.; Beldarrain, M.A.; Lopez, J.M.; Gonzalez- Fernandez, M.C.; Salazar, A.M.; Gandarias, R.B.; Borda, S.I.; Marques, N.O.; Amillano, M.B.; Zabaleta, M.C.; de Pancorbo, M.M. The COMT Val158 Met polymorphism as an associated risk factor for Alzheimer disease and mild cognitive impairment in APOE 4 carriers. BMC Neurosci., 2009, 10, 125.
50. Forero, D.A.; Benitez, B.; Arboleda, G.; Yunis, J.J.; Pardo, R.; Arboleda, H. Analysis of functional polymorphisms in three synaptic plasticity-related genes (BDNF, COMT AND UCHL1) in Alzheimer's disease in Colombia. Neurosci. Res., 2006, 55, 334-341.
51. Borroni, B.; Agosti, C.; Archetti, S.; Costanzi, C.; Bonomi, S.; Ghianda, D.; Lenzi, G.L.; Caimi, L.; Di Luca, M.; Padovani, A. Catechol-O-methyltransferase gene polymorphism is associated with risk of psychosis in Alzheimer Disease. Neurosci. Lett., 2004, 370, 127-129.
52. Sweet, R.A.; Devlin, B.; Pollock, B.G.; Sukonick, D.L.; Kastango, K.B.; Bacanu, S.A.; Chowdari, K.V.; DeKosky, S.T.; Ferrell, R.E. Catechol-O-methyltransferase haplotypes are associated with psychosis in Alzheimer disease. Mol. Psychiatry, 2005, 10, 1026-1036.
53. Borroni, B.; Grassi, M.; Costanzi, C.; Zanetti, M.; Archetti, S.; Franzoni, S.; Caimi, L.; Padovani, A. Haplotypes in cathechol-O- methyltransferase gene confer increased risk for psychosis in Alzheimer disease. Neurobiol. Aging, 2007, 28, 1231-1238.
54. Borroni, B.; Grassi, M.; Agosti, C.; Archetti, S.; Costanzi, C.; Cornali, C.; Caltagirone, C.; Caimi, L.; Di Luca, M.; Padovani, A. Cumulative effect of COMT and 5-HTTLPR polymorphisms and their interaction with disease severity and comorbidities on the risk of psychosis in Alzheimer disease Am. J. Geriatr. Psychiatry, 2006, 14, 343-351.
55. Blum, S.; Hebert, A.E.; Dash, P.K. A role for the prefrontal cortex in recall of recent and remote memories. Neuroreport, 2006, 17, 341-344.
56. Takashima, A.; Petersson, K.M.; Rutters, F.; Tendolkar, I.; Jensen, O.; Zwarts, M.J.; McNaughton, B.L.; Fernandez, G. Declarative memory consolidation in humans: a prospective functional magnetic resonance imaging study. Proc. Natl. Acad. Sci. USA, 2006, 103, 756-761.
57. Bertolino, A.; Rubino, V.; Sambataro, F.; Blasi, G.; Latorre, V.; Fazio, L.; Caforio, G.; Petruzzella, V.; Kolachana, B.; Hariri, A.; Meyer-Lindenberg, A.; Nardini, M.; Weinberger, D.R.; Scarabino, T. Prefrontal-hippocampal coupling during memory processing is modulated by COMT val158met genotype. Biol. Psychiatry, 2006, 60, 1250-1258.
58. de Frias, C.M.; Annerbrink, K.; Westberg, L.; Eriksson, E.; Adolfsson, R.; Nilsson, L.G. COMT gene polymorphism is associated with declarative memory in adulthood and old age. Behav. Genet., 2004, 34, 533-539.
59. Schott, B.H.; Seidenbecher, C.I.; Fenker, D.B.; Lauer, C.J.; Bunzeck, N.; Bernstein, H.G.; Tischmeyer, W.; Gundelfinger, E.D.; Heinze, H.J.; Duzel, E. The dopaminergic midbrain participates in human episodic memory formation: evidence from genetic imaging. J. Neurosci., 2006, 26, 1407-1417.
60. Di Giorgio, A.; Caforio, G.; Blasi, G.; Taurisano, P.; Fazio, L.; Romano, R.; Ursini, G.; Gelao, B.; Bianco, L.L.; Papazacharias, A.; Sinibaldi, L.; Popolizio, T.; Bellomo, A.; Bertolino, A. Catechol- O-methyltransferase Val158Met association with parahippocampal physiology during memory encoding in schizophrenia. Psychol. Med., 2010, 1-11.
61. Harris, S.E.; Wright, A.F.; Hayward, C.; Starr, J.M.; Whalley, L.J.; Deary, I.J. The functional COMT polymorphism, Val 158 Met, is associated with logical memory and the personality trait intellect/imagination in a cohort of healthy 79 year olds. Neurosci. Lett., 2005, 385, 1-6.
62. Liu, M.E.; Hong, C.J.; Liou, Y.J.; Tsai, Y.L.; Hsieh, C.H.; Association study of a functional catechol-O-methyltransferase polymorphism and executive function in elderly males without dementia. Neurosci. Lett., 2008, 436, 193-195.
63. Kane, M.J.; Engle, R.W. The role of prefrontal cortex in working-memory capacity, executive attention, and general fluid intelligence: an individual-differences perspective Psychon Bull. Rev., 2002, 9, 637-671.
64. Arnsten, A.F.; Li, B.M. Neurobiology of executive functions: catecholamine influences on prefrontal cortical functions. Biol. Psychiatry, 2005, 57, 1377-1384.
65. St Onge, J.R.; Floresco, S.B. Prefrontal cortical contribution to risk-based decision making. Cereb. Cortex, 2010, 20, 1816-1828.
66. Kable, J.W.; Glimcher, P.W. The neurobiology of decision: consensus and controversy. Neuron, 2009, 63, 733-745.
67. Cabeza, R. Hemispheric asymmetry reduction in older adults: the HAROLD model. Psychol. Aging, 2002, 17, 85-100.
68. Dolcos, F.; Rice, H.; Cabeza, R. Hemispheric asymmetry and aging: right hemisphere decline or asymmetry reduction. Neurosci. Biobehav. Rev., 2002, 26, 819-825.
69. Rajah, M.; D'Esposito, M. Region-specific changes in prefrontal function with age: a review of PET and fMRI studies on working and episodic memory. Brain, 2005, 128, 1964-1983.
70. Rajah, M.; Languay, R.; Valiquette, L. Age-related changes in prefrontal cortex activity are associated with behavioural deficits in both temporal and spatial context memory retrieval in older adults. Cortex, 2010, 46, 535-549.
71. Villain, N.; Chételat, G.; Desgranges, B.; Eustache, F. Neuroimaging in Alzheimer's disease: a synthesis and a contribution to the understanding of physiopathological mechanisms. Biol. Aujourdhui, 2010, 204, 145-158.
72. McGuinness, B.; Barrett, S.L.; Craig, D.; Lawson, J.; Passmore, A.P. Executive functioning in Alzheimer's disease and vascular dementia. Int. J. Geriatr. Psychiatry, 2010, 25, 562-568.
73. Huntley, J.D.; Howard, R.J. Working memory in early Alzheimer's disease: a neuropsychological review. Int. J. Geriatr. Psychiatry, 2010, 25, 121-132.
74. Zhou, B.; Zhao, Q.; Teramukai, S.; Ding, D.; Guo, Q.; Fukushima, M.; Hong, Z. Executive function predicts survival in Alzheimer disease: a study in Shanghai. J. Alzheimers Dis., 2010, 22, 673-682.
75. Gleichgerrcht, E.; Torralva, T.; Martinez, D.; Roca, M.; Manes, F. Impact of executive dysfunction on verbal memory performance in patients with Alzheimer's disease. J. Alzheimers Dis., 2011, 23, 79-85.
76. Woodward, M.; Brodaty, H.; Boundy, K.; Ames, D.; Blanch, G.; Balshaw, R. Does executive impairment define a frontal variant of Alzheimer's disease? Int. Psychogeriatr., 2010, 22, 1280-1290.
77. Musicco, M.; Salamone, G.; Caltagirone, C.; Cravello, L.; Fadda, L.; Lupo, F.; Mosti, S.; Perri, R.; Palmer, K. Neuropsychological predictors of rapidly progressing patients with Alzheimer's disease. Dement. Geriatr. Cogn. Disord., 2010, 30, 219-228.
78. Dickerson, B.C.; Wolk, D.A. Dysexecutive versus amnesic phenotypes of very mild Alzheimer's disease are associated with distinct clinical, genetic and cortical thinning characteristics. J. Neurol. Neurosurg. Psychiatry, 2011, 82, 45-51.
79. Swanberg, M.M.; Tractenberg, R.E.; Mohs, R.; Thal, L.J.; Cummings, J.L. Executive dysfunction in Alzheimer disease. Arch. Neurol., 2004, 61, 556-560.
80. Pereira, F.S.; Yassuda, M.S.; Oliveira, A.M.; Forlenza, O.V.Executive dysfunction correlates with impaired functional status in older adults with varying degrees of cognitive impairment. Int. Psychogeriatr., 2008, 20, 1104-1115.
81. McPherson, S.; Fairbanks, L.; Tiken, S.; Cummings, J.L.; Back- Madruga, C. Apathy and executive function in Alzheimer's disease. J. Int. Neuropsychol. Soc., 2002, 8, 373-381.
82. Esposito, F.; Rochat, L.; Van der Linden, A.C.; Lekeu, F.; Quittre, A.; Charnallet, A.; Van der Linden, M. Apathy and executive dysfunction in Alzheimer disease- Alzheimer Dis. Assoc. Disord., 2010, 24, 131-137.
83. Nagata, T.; Ishii, K.; Ito, T.; Aoki, K.; Ehara, Y.; Kada, H.; Furukawa, H.; Tsumura, M.; Shinagawa, S.; Kasahara, H.; Nakayama, K. Correlation between a reduction in Frontal Assessment Battery scores and delusional thoughts in patients with Alzheimer's disease. Psychiatry Clin. Neurosci., 2009, 63, 449-454.
84. Wirgenes, K.V.; Djurovic, S.; Sundet, K.; Agartz, I.; Mattingsdal, M.; Athanasiu, L.; Melle, I.; Andreassen, O.A. Catechol O- methyltransferase variants and cognitive performance in schizophrenia and bipolar disorder versus controls. Schizophr. Res., 2010, 122, 31-37.
85. de Frias, C.M.; Annerbrink, K.; Westberg, L.; Eriksson, E.; Adolfsson, R.; Nilsson, L.G. Catechol-O-methyltransferase Val158Met polymorphism is associated with cognitive performance in nondemented adults. J. Cog. Neurosci., 2005, 17, 1018-1025.
86. Wishart, H.A; Roth, R.M.; Saykin, A.J.; Rhodes, C.H.; Tsongalis, C.G.; Pattin, K.A.; Moore, G.H.; McAllister, T.W. COMT Val158Met Genotype and Individual Differences in Executive Function in Healthy Adults. J. Int. Neuropsychol., 2011, 17, 174-180.
87. Stowe, R.; Ives, N.; Clarke, C.E.; Handley, K.; Furmston, A.; Deane, K.; van Hilten, J.J.; Wheatley, K.; Gray, R. Meta-analysis of the comparative efficacy and safety of adjuvant treatment to levodopa in later Parkinson's disease. Mov. Disord., 2010, 26, 587-598.
88. Solla, P.; Cannas, A.; Marrosu, F.; Marrosu, M.G. Therapeutic interventions and adjustments in the management of Parkinson disease: role of combined carbidopa/levodopa/entacapone (Stalevo). Neuropsychiatr. Dis. Treat., 2010, 6, 483-490.
89. Di Giovanni, S.; Eleuteri, S.; Paleologou, K.E.; Yin, G.; Zweckstetter, M.; Carrupt, P.A.; Lashuel, H.A. Entacapone and tolcapone, two catechol O-methyltransferase inhibitors, block fibril formation of alpha-synuclein and beta-amyloid and protect against amyloid-induced toxicity. J. Biol. Chem., 2010, 285, 14941-14954.
90. Valkovic, P.; Benetin, J.; Blazicek, P.; Valkovicova, L.; Gmitterova, K.; Kukumberg, P. Reduced plasma homocysteine levels in levodopa/entacapone treated Parkinson patients. Parkinsonism Relat. Disord., 2005, 11, 253-256.
91. Muller, T.; Woitalla, D.; Muhlack, S. Inhibition of catechol-O- methyltransferase modifies acute homocysteine rise during repeated levodopa application in patients with Parkinson's disease. Naunyn Schmiedebergs Arch. Pharmacol., 2010, 383, 627-633.
92. Nevrly, M.; Kanovsky, P.; Vranova, H.; Langova, K.; Hlustik, P. Effect of entacapone on plasma homocysteine levels in Parkinson's disease patients. Neurol. Sci., 2010, 31, 565-569.
93. Liljequist, R.; Haapalinna, A.; Ahlander, M.; Li, Y.; Mannisto, P.T. Catechol O-methyltransferase inhibitor tolcapone has minor influence on performance in experimental memory models in rats. Behav. Brain Res., 1997, 82, 195-202.
94. Lapish, C.C.; Ahn, S.; Evangelista, L.M.; So, K.; Seamans, J.K.; Phillips, A.G. Tolcapone enhances food-evoked dopamine efflux and executive memory processes mediated by the rat prefrontal cortex. Psychopharmacology (Berl.), 2009, 202, 521-530.
95. Khromova, I.; Voronina, T.; Kraineva, V.A.; Zolotov, N.; Mannisto, P.T. Effects of selective catechol-O-methyltransferase inhibitors on single-trial passive avoidance retention in male rats. Behav. Brain Res., 1997, 80, 49-57.
96. Giakoumaki, S.G.; Roussos, P.; Bitsios, P. Improvement of prepulse inhibition and executive function by the COMT inhibitor tolcapone depends on COMT Val158Met polymorphism. Neuropsychopharmacology, 2008, 33, 3058-3068.
97. Apud, J.A.; Mattay, V.; Chen, J.; Kolachana, B.S.; Callicott, J.H.; Rasetti, R.; Alice, G.; Iudicello, J.E.; Akbar, N.; Egan, M.F.; Goldberg, T.E.; Weinberger, D. Tolcapone improves cognition and cortical information processing in normal human subjects. Neuropsychopharmacology, 2007, 32, 1011-1022.
98. Roussos, P.; Giakoumaki, S.G.; Bitsios, P. Tolcapone effects on gating, working memory, and mood interact with the synonymous catechol-O-methyltransferase rs4818c/g polymorphism. Biol. Psychiatry, 2009, 66, 997-1004.
99. Ioannidis, J.P; Boffetta, P.; Little, J.; O'Brien, T.R.; Uitterlinden, A.G.; Vineis, P.; Balding, D.J.; Chokkalingam, A.; Dolan, S.M.; Flanders, W.D.; Higgins, J.P.; McCarthy, M.I.; McDermott, D.H.; Page, G.P.; Rebbeck, T.R.; Seminara, D.; Khoury, M.J. Assessment of cumulative evidence on genetic associations: interim guidelines. Int. J. Epidemiol., 2008, 37, 120-132.